Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients

Phase 4CompletedNCT03011177

Handok Inc.168 enrolled

Overview

To assess the efficacy and safety of Teneligliptin and Linagliptin in the type 2 Diabetes Mellitus patients.

A randomized, open label, parallel-group, non-inferiority, active-controlled, phase IV study

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

168

Conditions

Type2 Diabetes Mellitus

Interventions

TeneligliptinDRUG

teneligliptin 20mg qd

LinagliptinDRUG

linagliptin 5mg qd

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who are 19 years or older on screening * Patients with type 2 diabetes mellitus * Patients with 7.0% ≤ HbA1c ≤ 11.0% at the screening visit * Patients with Fasting Plasma Glucose \<15mmol/L(270mg/dL) on screening Exclusion Criteria: \-

Locations (1)

Asan Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

HbA1c

Time frame: 12week

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.